Skip to content

Study on the effects of iron supplementation in patients with chronic heart failure

Parenteral iron supplementation, chemoreflex response, quality of life and exercise capacity in patients with chronic heart failure - PARIS-HF

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2012-005830-12-IT
Enrollment
Unknown
Registered
2012-12-28
Start date
2012-10-30
Completion date
Unknown
Last updated
2015-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic heart failure MedDRA version: 14.1 Level: SOC Classification code 10007541 Term: Cardiac disorders System Organ Class: 10007541 - Cardiac disorders

Interventions

Trade Name: FERINJECT*INF 5FL 2ML 50MG/ML Pharmaceutical Form: Solution for injection Other descriptive name: FERINJECT Concentration unit: mg milligram(s) Concentration type: up to Concentration numb

Sponsors

ISTITUTO AUXOLOGICO ITALIANO
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Chronic heart failure - Left ventricular ejection fraction =65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: - Acute heart failure - Uncontrolled hypertension - Unstable angina

Design outcomes

Primary

MeasureTime frame
Main Objective: Test the hypothesis that parenteral iron therapy in patients with chronic heart failure and iron deficiency anemia absolute or functional chemoriflessa can improve the sensitivity and the patient's overall clinical condition;Secondary Objective: - Assess possible relationships between changes in the parameters of iron metabolism and clinical and functional responses to intravenous iron therapy. - Identify between the different indices of iron metabolism analyzed what could best predict positive response to parenteral iron supplementation and better characterize the behavior of the indices of iron;Primary end point(s): Evaluation of complete blood count and parameters of iron metabolism;Timepoint(s) of evaluation of this end point: 3 weeks

Secondary

MeasureTime frame
Secondary end point(s): n.a.;Timepoint(s) of evaluation of this end point: n.a.

Countries

Italy

Contacts

Public ContactU.O. Cardiologia

Istituto Auxologico Italiano

gianfranco.parati@unimib.it02.619111

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026